Caplin Point Laboratories Limited (IN:CAPLIPOINT)
:CAPLIPOINT
Want to see IN:CAPLIPOINT full AI Analyst Report?
CAPLIPOINT Stock Chart & Stats
₹1845.95
-₹76.70(-2.97%)
At close: 4:00 PM EST
₹1845.95
-₹76.70(-2.97%)
Day’s Range― - ―
52-Week Range₹1,502.45 - ₹2,424.00
Previous CloseN/A
Volume128.91K
Average Volume (3M)3.75K
Market Cap
₹177.17B
Enterprise Value₹147.72B
Total Cash (Recent Filing)₹10.17B
Total Debt (Recent Filing)₹85.00M
Price to Earnings (P/E)28.5
Beta1.35
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.31%
Share Statistics
EPS (TTM)77.45
Shares Outstanding76,011,696
10 Day Avg. Volume2,866
30 Day Avg. Volume3,752
Financial Highlights & Ratios
PEG Ratio0.91
Price to Book (P/B)3.19
Price to Sales (P/S)5.23
P/FCF Ratio33.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)91.6
Revenue Forecast (FY)₹23.73B
Bulls Say, Bears Say
Bulls Say
Balance Sheet HealthCaplin Point's balance sheet shows ultra-low leverage and material equity growth, which limits financial risk and preserves flexibility for capex, regulatory compliance, or opportunistic M&A. This structural conservatism supports resilience across revenue cycles and funds long-term investment without forced financing.
Sustained ProfitabilityThe company sustains high gross margins (mid-50s) and healthy net margins (low-to-high 20s), reflecting strong product economics and pricing power in specialty generics. Durable margins support cash generation, attractive ROE (~19–20%), and the ability to reinvest in higher-complexity dosage forms over time.
Improving Cash GenerationOperating cash flow has meaningfully improved, roughly doubling in the period cited, and free cash flow has been positive and recently surged. Strong and improving cash generation underpins capital allocation flexibility, funds organic growth, supports working-capital needs, and reduces reliance on external financing.
Bears Say
Free Cash Flow VolatilityDespite overall positive cash generation, free cash flow has been uneven and fell sharply in FY2023, often running at roughly half of net income. This volatility—likely from working-capital swings or intermittent investments—makes predictable financing for dividends, buybacks, or acquisitions harder over a multi-quarter horizon.
Margin VolatilityRecent data show gross profit growth lagging revenue, producing margin compression and year-to-year swings in operating profitability. For a specialty generics player, sustained margin volatility can stem from input cost shifts, pricing pressure, or mix changes and may erode long-term earnings quality if not addressed.
ROE Pressure From Equity GrowthEquity expansion has funded asset growth and reduced leverage but creates a structural risk: if retained earnings or equity grow faster than net income, return on equity (~19–20%) may decline. Maintaining historical ROE will require commensurate profit growth or higher capital efficiency going forward.
Caplin Point Laboratories Limited News
CAPLIPOINT FAQ
What was Caplin Point Laboratories Limited’s price range in the past 12 months?
Caplin Point Laboratories Limited lowest stock price was ₹1502.45 and its highest was ₹2424.00 in the past 12 months.
What is Caplin Point Laboratories Limited’s market cap?
Caplin Point Laboratories Limited’s market cap is ₹177.17B.
When is Caplin Point Laboratories Limited’s upcoming earnings report date?
Caplin Point Laboratories Limited’s upcoming earnings report date is Aug 12, 2026 which is in 60 days.
How were Caplin Point Laboratories Limited’s earnings last quarter?
Caplin Point Laboratories Limited released its earnings results on May 14, 2026. The company reported ₹22.9 earnings per share for the quarter, beating the consensus estimate of N/A by ₹22.9.
Is Caplin Point Laboratories Limited overvalued?
According to Wall Street analysts Caplin Point Laboratories Limited’s price is currently Overvalued.
Does Caplin Point Laboratories Limited pay dividends?
Caplin Point Laboratories Limited pays a Quarterly dividend of ₹4 which represents an annual dividend yield of 0.31%. See more information on Caplin Point Laboratories Limited dividends here
What is Caplin Point Laboratories Limited’s EPS estimate?
Caplin Point Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Caplin Point Laboratories Limited have?
Caplin Point Laboratories Limited has 76,011,696 shares outstanding.
What happened to Caplin Point Laboratories Limited’s price movement after its last earnings report?
Caplin Point Laboratories Limited reported an EPS of ₹22.9 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 9.769%.
Which hedge fund is a major shareholder of Caplin Point Laboratories Limited?
Currently, no hedge funds are holding shares in IN:CAPLIPOINT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is a pharmaceutical firm actively involved in the development, manufacture, marketing, and export of both generic medications and proprietary branded products, primarily operating within India. Their extensive product portfolio encompasses a broad spectrum of pharmaceutical dosage forms, including various types of injections (liquid, lyophilized, IV infusions, powder for injection), oral preparations (tablets, liquid orals, capsules, softgel capsules, dry syrups), specialized applications (ophthalmic products, suppositories and ovules), and topical treatments (topicals, dermo cosmetics, inhalers). Beyond manufacturing, the company also manages an e-commerce platform named QueTenX. Established in 1990, Caplin Point Laboratories maintains its headquarters in Chennai, India.
Technical Analysis
Alembic Pharmaceuticals Limited
―
―
Granules India Limited
―
NATCO Pharma Limited
―
Neuland Laboratories Ltd.
―